Aurinia Pharmaceuticals Inc. appointed Joseph Hagan to the board.
Hagan is president and CEO of Regulus Therapeutics Inc.
Aurinia Pharmaceuticals appoints director
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Aurinia Pharmaceuticals Inc. appointed Joseph Hagan to the board.
Hagan is president and CEO of Regulus Therapeutics Inc.